Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Innocan Pharma plans listing on NYSE American by Jan. 30

Innocan Pharma expects to be listed on the NYSE American by January 30, 2026, subject to approval and compliance with exchange rules. The company is simultaneously considering, depending on market conditions and regulatory approval, a concurrent offering of securities; details will be provided in SEC and SEDAR+ filings. Common shares are expected to continue trading on the OTCQB until the close of trading on or about January 29; trading on the CSE under the ticker INNO will remain in place. Innocan reports a market capitalization of roughly $19.72 million, more cash than debt, a current ratio of 3.72, and a share price trading near its 52-week low. » Altro su de.investing.com
InnoCan Pharma reports Q3 EPS loss of CAD 0.49 and 20% revenue decline

For the quarter ended September 30, 2025, InnoCan Pharma reported an EPS loss of CAD 0.49 per share (year-ago: -CAD 0.090). Revenue fell to CAD 9.4 million from CAD 11.8 million in the year-ago quarter, a decline of 20.07%. The figures were presented at the financial conference for the quarter ended on November 26, 2025. » Altro su finanzen.net

Nell'ultimo trimestre, Innocan Pharma ha registrato ricavi pari a 5,51M€ e un utile netto di −828,08k€

Metrica	Valore
Capitalizzazione di mercato	+6,26M€
Numero di azioni	4,50M
Massimo/minimo a 52 settimane	+12,24€ - +1,37€
Dividendi	No
Beta	-0,22
Rapporto P/E	−4,92
Rapporto PEG	+0,05
Rapporto P/B	+1,40
Rapporto P/S	+0,29

Nome	Innocan Pharma
CEO	Iris Bincovich
Sede centrale	Calgary, ab Canada
Sito web	innocanpharma.com
Settore	Sanità
Industria	Fornitori e servizi sanitari
Dipendenti	11